Thanks , very informative . I see your point but BIT225 would still be more than adjunct . Ribavirin is destined for scrapheap too IMO .
There is a fair chance that BIT knocks the virus around enough for it to be a 100% effective in twin therapy with a polymerase . This test is what I look forward to .
MM has alluded to the next trial partner being polymerase .
I would hope they get a deal whereby they can fund a number of propositions IE: as the next trial would have to include Ribavirin at least but I would like see one run concurrent with just a polymerase for twleve weeks .
My hope is that will cure the disease .
7/8 EVR with just a one month of BIT225 dosing is a great result and compares well to any similar stage trial ever run for HCV especially any variant of genotype one .
When the inevitable big name pops up for partnership in the next trial the crowd will have to take notice . We need another trial and we need a partner . Fait accompli .
BIT Price at posting:
13.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)